Cancer Research

Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

11/25/2025

Excerpt from the Press Release: HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic…

Inflammasome Therapeutics to Collaborate with Sean M. Healey & AMG Center for ALS on a new treatment for Amyotrophic Lateral Sclerosis (ALS)

11/20/2025

Trial to Evaluate Inflammasome’s Kamuvudine-9 (K9) in Individuals with ALS Excerpt from the Press Release: NEWTON, Mass.–(BUSINESS WIRE)–Inflammasome Therapeutics (https://www.inflam.com), a clinical-stage biotech company developing a new class of drugs, Kamuvudines, for ophthalmic and neurological conditions, announced the company has signed a contract with The Sean M. Healey & AMG Center for ALS at Massachusetts…

Halifax doctor shocked by success of using heat to force cancer cell death

11/19/2025

Excerpt from the Press Release: There could be another option to treat cancer in the future, after a human trial proved to be extremely successful by raising the temperature of a tumour to kill it off. Dr. Carmen Giacomantonio, the chief medical officer for Halifax-based Sona Nanotech, used the idea that a fever helps kick-start…

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

11/18/2025

— Final ALPHA-STAR Phase 1b/2 Results from the Full-Enrollment Population (n=29) Remain Highly Consistent with Prior Results from the Target-Enrollment Population (n=16), Demonstrating Strong Efficacy, Favorable Safety, and Potential for Infrequent Dosing — — Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled…

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

11/17/2025

Excerpt from the Press Release: BOSTON and SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, and ImmunoScape, Pte. Ltd, a biotechnology company developing next-generation T…

Montai Therapeutics Presents Preclinical Data on NRF2 Agonist in Ulcerative Colitis at ACAAI Annual Meeting

11/13/2025

Program derived from Montai’s Anthromolecule chemistry demonstrates potent selectivity and efficacy against a triad of key mechanisms implicated in UC Company’s first development candidate to advance to IND-enabling studies Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Montai Therapeutics, a company harnessing AI to decode untapped, diverse chemistry to develop breakthrough medicines for chronic disease, will…

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

11/12/2025

Company Appoints Distinguished UCLA Oncology Surgeon to SAB, Enhancing Board’s Expertise in Surgical Oncology and Translational Oncology Research Aimed at Improving Multidisciplinary Treatment Strategies Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies…

Sonoma Biotherapeutics Announces Positive Interim Safety and Efficacy Data from Phase 1 REGULATE-RA Study of SBT-77-7101 in Refractory Rheumatoid Arthritis

11/10/2025

Favorable early safety profile with preliminary clinical and mechanistic evidence of therapeutic activity in refractory rheumatoid arthritis Data to be presented in a late-breaking oral presentation today 8:00 a.m. CT at the 2025 American College of Rheumatology (ACR) Convergence Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif. & SEATTLE–(BUSINESS WIRE)–Sonoma Biotherapeutics, Inc., a clinical-stage…

Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF

11/07/2025

Excerpt from the Press Release: WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive topline results from the Phase 1b Part B acute hemodynamic clinical trial of TX45, a long-acting, Fc-relaxin fusion protein, in patients with Group 2 PH‑HFrEF. The topline data showed that a single intravenous dose…

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

10/30/2025

No targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase 3 trial to support potential registration Excerpt from the Press Release: NEW YORK–(BUSINESS WIRE)– Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges…